Oxycodone for neuropathic pain and fibromyalgia in adults

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 8, 2013, Pages

  Gaskell, Helen ^a   Moore, R Andrew ^b   Derry, Sheena ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OXYCODONE;

ADULT; ARTICLE; CHRONIC PAIN; CLINICAL PROTOCOL; DATA COLLECTION METHOD; DRUG EFFICACY; DRUG SAFETY; EXPERIMENTAL DESIGN; FIBROMYALGIA; HUMAN; NEUROPATHIC PAIN; NUMERIC RATING SCALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SYSTEMATIC REVIEW; VISUAL ANALOG SCALE;

EID: 84906310078     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010692     Document Type: Article

References (60)

1. Apkarian AV, Hashmi JA, Baliki MN. Pain and the brain: specificity and plasticity of the brain in clinical chronic pain. Pain 2011;152(3 Suppl):S49-64. [DOI: 10.1016/j.pain.2010.11.010]
2. PaPaS author and referee guidance. http://papas.cochrane.org/papas-documents (accessed 22 January 2013).
3. Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136(3):380-7. [DOI: 10.1016/j.pain.2007.08.013]
4. Brennan MJ. The effect of opioid therapy on endocrine function. American Journal of Medicine 2013;126(3 Suppl 1):S12-8. [DOI: 10.1016/j.amjmed.2012.12.001]
5. Butler SF, Cassidy TA, Chilcoat H, Black RA, Landau C, Budman SH, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. Journal of Pain 2013;14(4):351-8. [DOI: 10.1016/j.jpain.2012.08.008]
6. Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD010111]
7. Derry S, Sven-Rice A, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD007393.pub3]
8. Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. Canadian Medical Association Journal 2009;181(12):891-6. [DOI: 10.1503/cmaj.090784]
9. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105-21. [DOI: 10.1016/j.jpain.2007.09.005]
10. Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD006146]
11. Gaskell H, Derry S, Moore RA, McQuay HJ. Single dose oral oxycodone and oxycodone plus paracetamol (acetaminophen) for acute postoperative pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD002763.pub2]
12. GustorffB, Dorner T, Likar R, Grisold W, Lawrence K, Schwarz F, et al. Prevalence of self-reported neuropathic pain and impact on quality of life: a prospective representative survey. Acta Anaesthesiologica Scandinavica 2008;52(1):132-6. [DOI: 10.1111/j.1399-6576.2007.01486.x]
13. Hall GC, Carroll D, McQuay HJ. Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005. BMC Family Practice 2008;9:26. [DOI: 10.1186/1471-2296-9-26]
14. Higgins JPT, Green S, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Altman DG, Sterne JAC editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
15. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12. [DOI: doi.org/10.1016/0197-2456(95)00134-4]
16. Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice AS, et al. A new definition of neuropathic pain. Pain 2011; Vol. 152, issue 10:2204-5. [DOI: 10.1016/j.pain.2011.06.017]
17. Kalso E. How different is oxycodone from morphine?. Pain 2007;132(3):227-8. [DOI: 10.1016/j.pain.2007.09.027]
18. Katusic S, Williams DB, Beard CM, Bergstralh EJ, Kurland LT. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945-1984. Neuroepidemiology 1991;10:276-81.
19. Khaliq W, Alam S, Puri N. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD004846.pub2]
20. Koopman JS, Dieleman JP, Huygen FJ, de Mos M, Martin CG, Sturkenboom MC. Incidence of facial pain in the general population. Pain 2009;147(1-3):122-7. [DOI: 10.1016/j.pain.2009.08.023]
21. Koroschetz J, Rehm SE, Gockel U, Brosz M, Freynhagen R, Tölle TR, et al. Fibromyalgia and neuropathic pain- differences and similarities: a comparison of 3057 patients with diabetic painful neuropathy and fibromyalgia. BMC Neurology 2011;11:55. [DOI: 10.1186/1471-2377-11-55]
22. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Annals of Internal Medicine 1987;107:224-33.
23. Lange B, Kuperwasser B, Okamoto A, Steup A, Häufel T, Ashworth J, et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Advances in Therapy 2010;27(6):381-99. [DOI: 10.1007/s12325-010-0036-3]
24. Liberati A, Altman DG, TetzlaffJ, Mulrow C, Gøtzsche PC, Ioannidiset JPA al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. Annals of Internal Medicine 2009;151(4):W-65-W-94.
25. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007115.pub2]
26. McNally JD, Matheson DA, Bakowsky VS. The epidemiology of self-reported fibromyalgia in Canada. Chronic Diseases in Canada 2006;27(1):9-16.
27. McQuay H, Moore R. An Evidence-Based Resource for Pain Relief. Oxford: Oxford University Press, 1998.
28. McQuay HJ, Smith LA, Moore RA. Chronic pain. In: Stevens A, Raftery J, Mant J, Simpson S editor(s). Health Care Needs Assessment. 3rd Edition. Oxford: Radcliffe Publishing, 2007. [ISBN: 978-1-84619-063-6]
29. Moisset X, Bouhassira D. Brain imaging of neuropathic pain. Neuroimaging 2007;37(Suppl 1):S80-8.
30. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything- large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209-16. [DOI: 10.1016/S0304-3959(98)00140-7]
31. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ISBN: 978-0-931092-69-5]
32. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2]
33. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2010;69(2):374-9. [DOI: [10.1136/ard.2009.107805]]
34. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al."Evidence" in chronic pain- establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386-9. [DOI: doi:10.1016/j.pain.2010.05.011]
35. Moore RA, Straube S, Derry S, McQuay HJ. Chronic low back pain analgesic studies--a methodological minefield. Pain 2010b;149(3):431-4. [DOI: 10.1016/j.pain.2010.02.032]
36. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2010;69(2):374-9. [DOI: doi:10.1136/ard.2009.107805]
37. Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ. Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 2010;149(2):360-4. [DOI: 10.1016/j.pain.2010.02.039]
38. Moore RA, Smugar SS, Wang H, Peloso PM, Gammaitoni A. Numbers-needed-to-treat analyses- do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials. Pain 2010;151(3):592-7. [DOI: doi:10.1016/j.pain.2010.07.013]
39. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD007938.pub2]
40. Moore RA, Straube S, Paine J, Derry S, McQuay HJ. Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain 2011;152(5):982-9. [DOI: doi:10.1016/j.pain.2010.11.030]
41. Moore RA, Mhuircheartaigh RJ, Derry S, McQuay HJ. Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion. European Journal of Anaesthesiology 2011;28(6):427-32. [DOI: 10.1097/EJA.0b013e328343c569]
42. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD008242.pub2]
43. Moore RA, Straube S, Eccleston C, Derry S, Aldington D, Wiffen P, et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain 2012;153(2):265-8. [DOI: 10.1016/j.pain.2011.10.004]
44. Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Practice 2013;March 6:Epub ahead of print. [DOI: 10.1111/papr.12050]
45. Moore RA, Straube S, Aldington D. Pain measures and cut-offs- 'no worse than mild pain' as a simple, universal outcome. Anaesthesia 2013;68(4):400-12. [DOI: 10.1111/anae.12148]
46. O'Brien EM, Staud RM, Hassinger AD, McCulloch RC, Craggs JG, Atchison JW, et al. Patient-centered perspective on treatment outcomes in chronic pain. Pain Medicine 2010;11(1):6-15. [DOI: 10.1111/j.1526-4637.2009.00685.x]
47. Olkkola KT, Hagelberg NM. Oxycodone: new 'old' drug. Current Opinions in Anasesthesiology 2009;22(4):459-62. [DOI: 10.1097/ACO.0b013e32832bc818]
48. Olkkola KT, Kontinen VK, Saari TI, Kalso EA. Does the pharmacology of oxycodone justify its increasing use as an analgesic?. Trends in Pharmacological Sciences 2013;34(4):206-14. [DOI: 10.1016/j.tips.2013.02.001]
49. Poyhia R, Vainio A, Kalso E. A review of oxycodone's clinical pharmacokinetics and pharmacodynamics. Journal of Pain & Symptom Management 1993;8(2):63-7.
50. Rappaport ZH, Devor M. Trigeminal neuralgia: the role of self-sustaining discharge in the trigeminal ganglion. Pain 1994;56:127-38. [DOI: 10.1016/0304-3959(94)90086-8]
51. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
52. Soni A, Batra R, Gwilym S, Spector T, Hart D, Arden N, et al. Neuropathic features of joint pain: a community-based study. Arthritis & Rheumatism 2013;April 1:Epub ahead of print. [DOI: 10.1002/art.37962]
53. Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. British Journal of Clinical Pharmacology 2008;66(2):266-75. [DOI: 10.1111/j.1365-2125.2008.03200.x]
54. Straube S, Derry S, Moore RA, Paine J, McQuay HJ. Pregabalin in fibromyalgia- responder analysis from individual patient data. BMC Musculoskeletal Disorders 2010;11:150. [doi: 10.1186/1471-2474-11-150]
55. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology 2008;8:29. [DOI: 10.1186/1471-2377-8-29]
56. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin: results from a general population survey. Journal of Pain 2006;7(4):281-9. [DOI: 10.1016/j.jpain.2005.11.008]
57. Tracey I. Can neuroimaging studies identify pain endophenotypes in humans?. Nature Reviews Neurology 2011;7(3):173-81. [doi: 10.1038/nrneurol.2011.4]
58. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70(18):1630-5.
59. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis and Rheumatism 1990;33:160-72.
60. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care and Research 2010;62:600-10. [DOI: 10.1002/acr.20140]